Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG08 Ocrelizumab
D05218 Ocrelizumab (USAN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Multiple Sclerosis Agents
Ocrelizumab
D05218 Ocrelizumab (USAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD20
D05218 Ocrelizumab (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05218
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05218
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05218
